본문바로가기
About Us
SK bioscience
Company Overview
History
Vision
Contact Us
Leadership
Message from the CEO
Headquarters & Facilities
SK bioscience Headquarters
R&D Center
L HOUSE
Subsidiary
SK bioscience USA
IDT Biologika
Science & Technology
Pipeline
R&D
Production
Business
Business Overview
Domestic
Overseas Business
Vaccine Co-Development
and Technology Transfer
CDMO/CMO
Products
In-house Products
Outsourced Products
Global Partnerships
ESG
새창열기 아이콘
IR
Corporate Governance
Company Information
Financial Information
Financial Statements
Financial Credit
Audit Reports
Investment Information
Stock Prices
Shareholder Status
IR Documents
Disclosure
PR
Press Releases
Media Zoom
Brochure
CI Guideline
sitemap
About Us
SK bioscience
Company Overview
History
Vision
Contact Us
Leadership
Message from the CEO
Headquarters & Facilities
SK bioscience Headquarters
R&D Center
L HOUSE
Subsidiary
SK bioscience USA
IDT Biologika
Science & Technology
Pipeline
R&D
Production
Business
Business Overview
Domestic
Overseas Business
Vaccine Co-Development
and Technology Transfer
CDMO/CMO
Products
In-house Products
Outsourced Products
Global Partnerships
ESG
IR
Corporate Governance
Company Information
Financial Information
Financial Statements
Financial Credit
Audit Reports
Investment Information
Stock Prices
Shareholder Status
IR Documents
Disclosure
PR
Press Releases
Media Zoom
Brochure
CI Guideline
사이트맵 닫기
Language
KOR
ENG
LinkedIn
YouTube
ESG
SK careers
C/S
SK ethics
Q
U
I
C
K
PR
SK bioscience company news updates
PR
About Us
Science & Technology
Business
ESG
IR
PR
Press Releases
Press Releases
Media Zoom
Brochure
CI Guideline
Press releases
SK bioscience Earns ‘A’ Rating in KCGS ESG Assessment for Fourth Consecutive Year
2025.11.19
IDT Biologika Accelerates Global CDMO Expansion Manufacturing capabilities highlighted through consecutive participation in WVC, CPHI and BIO-Europe 2025
2025.11.05
SK bioscience strengthens global vaccine partnerships to expand R&D pipeline competitiveness
2025.10.29
SK bioscience Files for First-in-Human Trial of Universal Coronavirus Vaccine (Pan-sarbecovirus Vaccine) GBP511 Phase 1/2 study in Australia
2025.10.15
SK bioscience Announces Start of RSV Preventive Antibody Administration for 2025-2026 Season
2025.10.02
SK bioscience Launches Influenza Vaccination Campaign Ahead of Flu Season “Get Vaccinated Before the Chuseok Holiday to Protect Your Family’s Health”
2025.09.29
SK bioscience Submits IND for Phase 3 Clinical Trial of 2-Dose Varicella Vaccine
2025.09.02
SK bioscience Successfully Concludes Nationwide Symposium Series on RSV Preventive Antibody ‘Beyfortus’
2025.08.29
SK Group Chairman Taewon Chey and Bill Gates to Strengthen Cooperation in Energy and Biotechnology
2025.08.22
SK bioscience Discusses Collaboration with the Gates Foundation to Advance Global Health
2025.08.21
처음
이전
1
2
3
4
5
6
7
8
9
10
다음
끝
